MedPath

Clinical study to evaluate the efficacy and safety of LH-RH agonist alternative therapy on prostate cancer patients who relapsed after combined androgen blockade.

Phase 2
Recruiting
Conditions
Prostate cancer
Registration Number
JPRN-UMIN000007771
Lead Sponsor
Department of Urology, Ibaraki Prefecture Central Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who have not observed anti-androgen withdrawal syndrome(AWS) 2)Treated with steroid drug 3)Undergone bilateral orchidectomy 4)Treated with chemotherapy 5)Treated with anti-androgen for benign prostate hyperplasia(BPH) 6)Considered inappropriate for this study by physicians

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath